Medical School · Year 3 · Psychiatry · includes a quiz and discussion video

Seminar 07: Psychotic Disorders

Year 3: Psychiatry Clerkship

Learning Objectives

By the end of this seminar, students will be able to:

1. Define psychosis and its key features
2. Diagnose schizophrenia using DSM-5 criteria
3. Differentiate schizophrenia spectrum disorders
4. Recognize prodromal symptoms and early intervention
5. Apply antipsychotic treatment principles
6. Manage acute psychosis safely

Seminar Outline

I. Overview of Psychosis

Psychosis represents a syndrome characterized by loss of contact with reality, manifested through hallucinations, delusions, disorganized thinking, and disorganized or abnormal motor behavior. Importantly, psychosis is not itself a diagnosis but rather a clinical syndrome that occurs across numerous psychiatric, medical, and substance-related conditions. The experience of psychosis varies considerably in severity, ranging from subtle perceptual disturbances to florid breaks with reality that severely impair functioning and safety. Understanding psychosis requires appreciation of its diverse presentations and underlying causes to guide appropriate evaluation and treatment.

The differential diagnosis of psychosis spans primary psychotic disorders, mood disorders with psychotic features, substance-induced states, and medical conditions. Primary psychotic disorders include schizophrenia, schizoaffective disorder, brief psychotic disorder, schizophreniform disorder, and delusional disorder. Mood disorders may present with psychotic features, including bipolar disorder during manic or depressive episodes and major depressive disorder with psychotic features. Substance-induced psychosis can result from intoxication with stimulants, cannabis, hallucinogens, or other substances, as well as from alcohol withdrawal. Medical conditions including delirium, dementia, autoimmune encephalitis, seizure disorders, and brain tumors may present with psychotic symptoms and must be carefully ruled out.

Schizophrenia, the prototypical primary psychotic disorder, has a lifetime prevalence of approximately one percent across populations worldwide. The typical age of onset is late adolescence to early thirties, with males tending to present earlier than females. The course is chronic in most cases, though outcomes vary considerably from relatively good functional recovery to severe persistent impairment. Life expectancy is reduced by fifteen to twenty years compared to the general population, primarily due to cardiovascular disease, metabolic conditions, and suicide. The substantial disability and mortality associated with schizophrenia underscore the importance of effective treatment.

The etiology of schizophrenia involves complex interactions among genetic, neurodevelopmental, and environmental factors. Heritability is approximately eighty percent, with first-degree relatives having tenfold elevated risk. Neurodevelopmental factors include prenatal and perinatal complications, maternal infection, and early neurodevelopmental abnormalities. The dopamine hypothesis posits that mesolimbic dopaminergic hyperactivity underlies positive symptoms, supported by the efficacy of dopamine-blocking antipsychotics. Environmental factors including urban upbringing, migration, childhood adversity, and cannabis use increase risk, particularly in genetically vulnerable individuals. Current models emphasize gene-environment interactions in the pathophysiology of schizophrenia.

<image>Panel A: A diagram showing the differential diagnosis of psychosis organized by primary psychotic, mood-related, substance-induced, and medical categories. Panel B: A bar graph showing epidemiological data for schizophrenia including prevalence, age of onset, and mortality. Panel C: A pie chart showing the relative contributions of genetic versus environmental factors in schizophrenia etiology. Panel D: A schematic of the dopamine hypothesis showing mesolimbic hyperactivity and mesocortical hypoactivity.</image>

II. Symptoms of Schizophrenia

Positive symptoms of schizophrenia represent additions to or exaggerations of normal experience and include hallucinations, delusions, disorganized speech, and disorganized or catatonic behavior. These symptoms are termed positive because they represent the presence of abnormal phenomena rather than the absence of normal functions. Positive symptoms tend to be the most dramatic and recognizable features of psychosis and typically respond well to antipsychotic medication. The severity of positive symptoms often fluctuates over time, with acute exacerbations during psychotic episodes and relative quiescence during periods of stability.

Hallucinations are perceptions occurring in the absence of corresponding external stimuli. Auditory hallucinations are the most common type in schizophrenia, typically experienced as voices that may be single or multiple, familiar or unfamiliar, and may provide commentary on the patient's actions, converse with each other, or give commands. Command hallucinations directing the patient to harm themselves or others require careful safety assessment. Visual hallucinations are less common in primary psychotic disorders and should raise suspicion for organic causes including delirium, substance intoxication, or neurological conditions. Tactile, olfactory, and gustatory hallucinations occur less frequently.

Delusions are fixed false beliefs that are not amenable to change despite conflicting evidence and are not shared by others of similar cultural or religious background. Persecutory delusions, involving belief that one is being harmed, harassed, or conspired against, represent the most common type. Referential delusions involve belief that environmental events, media, or others' comments have special personal significance. Grandiose delusions involve inflated beliefs about one's abilities, identity, or importance. Other delusion types include erotomanic delusions about another person being in love with the patient, somatic delusions about body functioning, delusions of control involving belief that one's actions are controlled by external forces, and thought delusions involving belief that thoughts are being inserted, withdrawn, or broadcast to others.

Negative symptoms represent diminutions or losses of normal functions and include alogia or poverty of speech, avolition or lack of motivation, anhedonia or inability to experience pleasure, asociality or social withdrawal, and flat or blunted affect or reduced emotional expression. Negative symptoms are often more persistent and debilitating than positive symptoms, contributing significantly to functional impairment and disability. Unfortunately, negative symptoms respond less well to antipsychotic medication than positive symptoms, representing an important unmet treatment need. Distinguishing primary negative symptoms from secondary negative symptoms caused by depression, medication side effects, or social deprivation guides treatment selection.

<image>Panel A: A categorization of positive symptoms showing hallucinations, delusions, and disorganization with examples. Panel B: A diagram of hallucination types organized by sensory modality with frequency in schizophrenia. Panel C: A chart of delusion types with definitions and characteristic examples. Panel D: A visual representation of the five negative symptoms with their impact on functioning.</image>

III. Schizophrenia Diagnosis

The DSM-5 diagnostic criteria for schizophrenia require the presence of at least two characteristic symptoms during a significant portion of time during a one-month period, with at least one of the two being from the core symptom group of delusions, hallucinations, or disorganized speech. The full list of Criterion A symptoms includes delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms. Criterion B requires that functioning in one or more major areas such as work, interpersonal relations, or self-care is markedly below the level achieved prior to onset. Continuous signs of the disturbance must persist for at least six months, including at least one month of active-phase symptoms.

The six-month duration requirement includes prodromal or residual periods during which symptoms may be attenuated or limited to negative symptoms, distinguishing schizophrenia from briefer psychotic presentations. Schizoaffective disorder and mood disorder with psychotic features must be ruled out by demonstrating that any major depressive or manic episodes occurring during the illness have been present for a minority of the total illness duration and that psychotic symptoms have occurred for at least two weeks in the absence of mood symptoms. The symptoms must not be attributable to substances or medical conditions.

Course specifiers in DSM-5 characterize the current status and trajectory of schizophrenia. First episode currently in acute episode describes patients presenting with their first psychotic episode with active symptoms. First episode currently in partial or full remission indicates symptom improvement following the initial episode. Multiple episodes with various remission states apply to patients who have experienced more than one episode. Continuous specifier applies when symptoms remain throughout the observation period without remission. The with catatonia specifier is added when the clinical picture is characterized by marked psychomotor disturbance.

Cognitive symptoms, while not part of the diagnostic criteria, represent an important clinical feature of schizophrenia that significantly impacts functional outcomes. Deficits commonly occur in attention, working memory, processing speed, executive function, and social cognition. Cognitive impairment often precedes psychotic symptoms and persists independent of symptom fluctuations, representing a stable feature of the illness. Cognitive deficits predict functional outcomes including employment, independent living, and social functioning better than positive symptoms. Unfortunately, current treatments have limited efficacy for cognitive symptoms, making this an important area for treatment development.

<image>Panel A: A checklist format display of DSM-5 Criterion A symptoms with the one-of-three requirement highlighted. Panel B: A timeline showing the six-month duration requirement including prodromal, active, and residual phases. Panel C: A flowchart for differentiating schizophrenia from schizoaffective and mood disorders with psychosis. Panel D: A cognitive domains diagram showing typical deficits in schizophrenia and their functional impact.</image>

IV. Schizophrenia Spectrum Disorders

Brief psychotic disorder involves the presence of at least one positive psychotic symptom, specifically delusions, hallucinations, disorganized speech, or grossly disorganized or catatonic behavior, lasting at least one day but less than one month with eventual full return to premorbid functioning. The diagnosis may be specified as with marked stressor when symptoms develop shortly after events that would be markedly stressful to almost anyone, or without marked stressor. Brief psychotic disorder may also occur with peripartum onset when symptoms begin during pregnancy or within four weeks postpartum. The prognosis is generally good, though some patients eventually develop schizophrenia or other persistent psychotic disorders.

Schizophreniform disorder applies when the essential features of schizophrenia are present but the duration is at least one month but less than six months. The diagnosis should be made provisionally when assigned before recovery, as it may be changed to schizophrenia if symptoms persist beyond six months. Good prognostic features include acute onset, confusion or perplexity at height of psychotic episode, good premorbid social and occupational functioning, and absence of blunted or flat affect. Approximately one-third of patients with schizophreniform disorder recover, while the remainder progress to schizophrenia or schizoaffective disorder.

Schizoaffective disorder requires an uninterrupted period of illness during which there is a major mood episode concurrent with symptoms meeting Criterion A for schizophrenia. The critical distinguishing feature is that delusions or hallucinations must have been present for at least two weeks in the absence of a major mood episode during the lifetime duration of the illness. Major depressive or manic symptoms must be present for a majority of the total duration of the active and residual periods of the illness. Schizoaffective disorder is specified as bipolar type if the disturbance includes manic episodes or as depressive type if only depressive episodes have occurred.

Delusional disorder involves the presence of one or more delusions with a duration of one month or longer without meeting full criteria for schizophrenia. Criterion A for schizophrenia has never been met, though hallucinations, if present, are not prominent and are related to the delusional theme. Functioning is not markedly impaired, and behavior is not obviously bizarre or odd apart from the impact of the delusion. Subtypes include erotomanic, grandiose, jealous, persecutory, somatic, mixed, and unspecified. Delusional disorder is distinguished by relatively preserved functioning and the non-bizarre quality of delusions, meaning the delusional content involves situations that could conceivably occur.

<image>Panel A: A comparison chart of schizophrenia spectrum disorders showing duration criteria and distinguishing features. Panel B: A decision flowchart for differentiating brief psychotic disorder, schizophreniform disorder, and schizophrenia based on duration. Panel C: A Venn diagram illustrating schizoaffective disorder's relationship to schizophrenia and mood disorders. Panel D: A classification of delusional disorder subtypes with characteristic content.</image>

V. Differential Diagnosis

Medical causes of psychosis must be carefully considered and ruled out, particularly in first presentations, atypical presentations, and older patients. Neurological conditions causing psychosis include seizure disorders, particularly temporal lobe epilepsy, brain tumors, stroke, traumatic brain injury, Parkinson disease, Huntington disease, and various dementias. Metabolic derangements including electrolyte abnormalities, uremia, hepatic encephalopathy, and hypoglycemia may present with psychosis. Endocrine disorders including thyroid dysfunction, adrenal disorders, and parathyroid abnormalities can cause psychiatric symptoms. Infectious causes include HIV, neurosyphilis, and various forms of encephalitis. Anti-NMDA receptor encephalitis, an autoimmune condition, is an important and treatable cause of psychosis that may be missed without appropriate testing.

Substance-induced psychosis results from intoxication with or withdrawal from various substances. Stimulants including cocaine, amphetamines, and methamphetamine commonly cause paranoid psychosis during intoxication. Cannabis use can trigger psychotic symptoms and may precipitate onset of schizophrenia in vulnerable individuals. Hallucinogens including LSD and PCP produce acute psychotic symptoms. Alcohol withdrawal can cause hallucinations and delusions, particularly during delirium tremens. Certain medications including corticosteroids and anticholinergics may induce psychosis. Substance-induced psychosis typically resolves with abstinence, though symptoms may persist for weeks to months in some cases.

Mood disorders with psychotic features represent an important differential consideration. Bipolar I disorder with psychotic features involves psychosis occurring exclusively during manic or depressive episodes, with psychotic content often mood-congruent such as grandiose delusions during mania or nihilistic delusions during depression. Major depressive disorder with psychotic features similarly involves psychosis only during depressive episodes. The key distinguishing feature from schizoaffective disorder is that psychotic symptoms do not occur independent of mood episodes. Treatment emphasizes mood stabilization with antipsychotics as adjunctive rather than primary treatment.

Medical workup for first-episode psychosis should include comprehensive evaluation to rule out secondary causes. Basic laboratory testing includes complete blood count, comprehensive metabolic panel, thyroid function tests, vitamin B12 level, HIV testing, and syphilis serologies. Urine drug screen identifies substance contributions. Brain imaging with CT or MRI is indicated to rule out structural abnormalities. Lumbar puncture should be performed if encephalitis is suspected, with testing for anti-NMDA receptor and other autoimmune antibodies. EEG may be useful if seizure disorder is suspected. The extent of workup is guided by clinical presentation and suspicion for secondary causes.

<image>Panel A: A comprehensive list of medical causes of psychosis organized by organ system. Panel B: A chart of substances causing psychosis with characteristic features of each. Panel C: A comparison of schizophrenia versus mood disorders with psychosis showing distinguishing features. Panel D: A medical workup algorithm for first-episode psychosis showing initial and extended testing.</image>

VI. Early Psychosis and Prodrome

The prodromal phase of schizophrenia represents the period preceding the first clear psychotic episode during which nonspecific symptoms and functional decline may be evident. Prodromal symptoms include attenuated positive symptoms such as unusual perceptual experiences or odd beliefs that do not reach the threshold of frank psychosis, negative symptoms including social withdrawal and declining interest in activities, cognitive symptoms with declining academic or work performance, mood symptoms including depression and anxiety, and behavioral changes such as sleep disturbance, decreased self-care, and suspiciousness. Recognition of the prodrome offers opportunity for early intervention that may improve outcomes.

Clinical high risk states describe individuals who demonstrate features suggesting elevated probability of developing psychosis. Criteria typically include attenuated psychotic symptoms, brief limited intermittent psychotic symptoms that resolve spontaneously, or genetic risk combined with functional decline. Structured assessment tools including the Structured Interview for Prodromal Syndromes and the Comprehensive Assessment of At-Risk Mental States provide standardized approaches to identifying high-risk individuals. Transition rates to psychosis range from fifteen to thirty-five percent over two to three years, meaning most high-risk individuals do not develop psychotic disorders, while conversely many who develop psychosis were not identified as high-risk.

First-episode psychosis represents a critical intervention opportunity, as duration of untreated psychosis strongly predicts long-term outcomes. Longer duration of untreated psychosis is associated with poorer treatment response, greater symptom severity, worse cognitive outcomes, and poorer functional recovery. First-episode psychosis programs providing coordinated specialty care have demonstrated superior outcomes compared to usual care. These programs emphasize rapid engagement, low-dose antipsychotic treatment, individual and family therapy, supported employment and education, and case management. Early treatment may alter illness trajectory and improve long-term prognosis.

Components of early intervention services for psychosis include pharmacological treatment with careful attention to using minimal effective doses given the sensitivity of first-episode patients to side effects. Cognitive behavioral therapy for psychosis helps patients understand and cope with symptoms. Family education and support reduces expressed emotion and improves outcomes. Supported employment and education programs help maintain functioning during the critical early illness period. Case management provides coordination and support. These comprehensive approaches represent the standard of care for first-episode psychosis and should be accessible to all patients presenting with new-onset psychotic disorders.

<image>Panel A: A timeline showing the progression from premorbid through prodromal to psychotic phases with characteristic features. Panel B: A diagram of clinical high risk criteria and transition rates. Panel C: A graph showing the relationship between duration of untreated psychosis and outcomes. Panel D: A model of comprehensive first-episode psychosis services showing component interventions.</image>

VII. Antipsychotic Medications Overview

Antipsychotic medications are the mainstay of pharmacological treatment for schizophrenia and other psychotic disorders. First-generation antipsychotics, also called typical antipsychotics or conventional antipsychotics, act primarily through dopamine D2 receptor blockade in the mesolimbic pathway, reducing positive symptoms. Second-generation antipsychotics, also called atypical antipsychotics, additionally antagonize serotonin 5-HT2A receptors and have varying receptor profiles contributing to their clinical effects. Both classes are effective for positive symptoms, with limited efficacy for negative and cognitive symptoms. Clozapine is uniquely effective for treatment-resistant schizophrenia and represents the only medication with proven superiority.

First-generation antipsychotics include high-potency agents such as haloperidol and fluphenazine, which have strong D2 blockade and higher risk of extrapyramidal symptoms but less sedation and hypotension, and low-potency agents such as chlorpromazine, which have weaker D2 affinity but greater sedation, hypotension, and anticholinergic effects. Haloperidol remains widely used, particularly in acute settings, due to availability of intramuscular formulation and rapid onset. Long-acting injectable formulations of haloperidol and fluphenazine provide options for maintenance treatment. First-generation antipsychotics remain clinically useful despite the availability of newer agents.

Second-generation antipsychotics have become first-line treatment due to lower extrapyramidal side effect risk, though metabolic effects have emerged as significant concerns. Risperidone is highly effective with dose-dependent extrapyramidal symptoms at higher doses. Olanzapine is efficacious but carries significant metabolic risk. Quetiapine is sedating with lower extrapyramidal risk. Aripiprazole and brexpiprazole are partial dopamine agonists with favorable metabolic profiles. Ziprasidone is weight-neutral but carries QTc prolongation risk. Lurasidone has favorable metabolic profile and must be taken with food. Paliperidone is the active metabolite of risperidone with simplified dosing.

Selection among antipsychotic medications should be individualized based on prior response, side effect profile, patient preferences, and specific clinical features. Prior response to a specific medication strongly predicts future response and should guide selection. Side effect profiles should be matched to patient concerns, with metabolic effects being particularly important given high rates of cardiovascular disease in schizophrenia. Route of administration options include oral, orally disintegrating, liquid, short-acting injectable, and long-acting injectable formulations. Cost considerations may influence selection, particularly given wide variation among medications.

<image>Panel A: A comparison of first-generation versus second-generation antipsychotic mechanisms and receptor profiles. Panel B: A chart of first-generation antipsychotics showing potency and characteristic side effects. Panel C: A comparison table of second-generation antipsychotics showing efficacy and side effect profiles. Panel D: A decision algorithm for antipsychotic selection based on patient factors.</image>

VIII. Antipsychotic Side Effects

Metabolic effects represent the most clinically significant adverse effects of many second-generation antipsychotics and contribute to the elevated cardiovascular mortality in schizophrenia. Weight gain varies substantially across medications, with olanzapine and clozapine carrying highest risk, quetiapine and risperidone intermediate risk, and aripiprazole, ziprasidone, and lurasidone lower risk. New-onset diabetes occurs at elevated rates, requiring baseline and ongoing glucose monitoring. Dyslipidemia, including elevated triglycerides and LDL cholesterol, adds to cardiovascular risk. Metabolic monitoring should include baseline measurements and regular follow-up of weight, waist circumference, blood pressure, fasting glucose, and lipid panel. Lifestyle interventions and medication switching should be considered when significant metabolic changes occur.

Extrapyramidal symptoms result from dopamine D2 blockade in the nigrostriatal pathway and include several distinct syndromes. Acute dystonia involves sustained muscle contractions, often affecting neck, jaw, or eyes, typically occurring within days of starting or increasing medication, treated acutely with anticholinergic medications such as benztropine or diphenhydramine. Akathisia is a subjective sense of inner restlessness with an inability to sit still, often very distressing, treated with beta-blockers, dose reduction, or medication switch. Parkinsonism features tremor, rigidity, and bradykinesia similar to Parkinson disease, managed with dose reduction or anticholinergic medications. These acute extrapyramidal effects are more common with high-potency first-generation antipsychotics and risperidone at higher doses.

Tardive dyskinesia is a late-onset movement disorder characterized by involuntary, repetitive movements, most commonly involving the orofacial region with lip smacking, tongue protrusion, and chewing movements, but potentially affecting any body region. Risk increases with cumulative antipsychotic exposure, older age, and female sex. Unlike acute extrapyramidal symptoms, tardive dyskinesia often persists despite medication discontinuation and may be irreversible. Prevention through using minimal effective doses and monitoring with tools such as the Abnormal Involuntary Movement Scale is essential. Valbenazine and deutetrabenazine are FDA-approved for tardive dyskinesia treatment. Clozapine has the lowest tardive dyskinesia risk among antipsychotics.

Neuroleptic malignant syndrome is a rare but life-threatening reaction to antipsychotic medications characterized by hyperthermia, severe muscle rigidity, autonomic instability, and altered mental status. Laboratory findings include markedly elevated creatine kinase and leukocytosis. The syndrome represents a medical emergency requiring immediate antipsychotic discontinuation, supportive care including cooling and hydration, and potentially pharmacological treatment with dantrolene for rigidity and bromocriptine as a dopamine agonist. Intensive care unit admission is typically required. After recovery, cautious rechallenge with a different antipsychotic may be considered after a medication-free period.

<image>Panel A: A metabolic risk comparison across antipsychotics with monitoring recommendations. Panel B: A clinical features guide to extrapyramidal syndromes showing onset timing and treatment. Panel C: A diagram of tardive dyskinesia showing common movement patterns and risk factors. Panel D: A clinical features and management algorithm for neuroleptic malignant syndrome.</image>

IX. Treatment-Resistant Schizophrenia and Clozapine

Treatment-resistant schizophrenia is defined as inadequate response to at least two adequate trials of antipsychotic medications at therapeutic doses for sufficient duration. An adequate trial generally requires six to eight weeks at a therapeutic dose with documented adherence. Approximately thirty percent of patients with schizophrenia meet criteria for treatment resistance. Before concluding that a patient has treatment-resistant illness, clinicians should verify adherence, ensure adequate dosing, confirm the diagnosis, and address complicating factors such as substance use. Treatment-resistant schizophrenia carries significant morbidity and represents an indication for clozapine.

Clozapine is the only antipsychotic with demonstrated superiority for treatment-resistant schizophrenia and should be offered to all patients meeting treatment resistance criteria. Beyond efficacy for positive symptoms, clozapine reduces suicide risk, reduces aggression, and may improve negative symptoms and quality of life. Despite these benefits, clozapine is substantially underutilized, prescribed to only a small fraction of eligible patients. Barriers to clozapine use include required monitoring, concern about side effects, lack of prescriber familiarity, and patient reluctance. Expanding clozapine access represents an important clinical priority given its unique benefits.

Clozapine monitoring is required due to risk of agranulocytosis, a potentially fatal decrease in neutrophil count occurring in approximately one percent of patients. The Risk Evaluation and Mitigation Strategy program requires registration of prescribers, pharmacies, and patients, with mandatory absolute neutrophil count monitoring and documentation before each dispensing. Monitoring is weekly for the first six months, biweekly for the next six months, then monthly thereafter. Treatment must be interrupted if absolute neutrophil count falls below one thousand and permanently discontinued if below five hundred. Additional monitoring addresses other clozapine side effects.

Other clozapine side effects requiring monitoring and management include myocarditis occurring primarily in the first month of treatment, presenting with fever, tachycardia, chest pain, and elevated troponin. Seizure risk is dose-related, primarily at doses above five hundred milligrams, and may be managed with anticonvulsants if clozapine continuation is necessary. Constipation can be severe, progressing to ileus, requiring prophylactic bowel regimens. Sialorrhea or excessive salivation is common and bothersome, potentially managed with glycopyrrolate or other interventions. Metabolic effects are substantial, requiring aggressive monitoring and management.

<image>Panel A: A definition and diagnostic framework for treatment-resistant schizophrenia. Panel B: A comparison of clozapine efficacy outcomes versus other antipsychotics. Panel C: A detailed clozapine monitoring protocol showing ANC thresholds and timing. Panel D: A management guide for common clozapine side effects.</image>

X. Long-Term Management and Recovery

Long-acting injectable antipsychotics provide an important option for maintenance treatment, ensuring consistent medication delivery independent of daily adherence decisions. Available long-acting formulations include paliperidone palmitate given monthly or every three months, risperidone microspheres given every two weeks, olanzapine pamoate given every two to four weeks, aripiprazole and aripiprazole lauroxil given monthly or every two months, and haloperidol and fluphenazine decanoate given every two to four weeks. Long-acting injectables reduce relapse and hospitalization rates compared to oral medications, likely through improved adherence. These formulations should be considered early in treatment rather than reserved for patients with demonstrated non-adherence.

Psychosocial treatments complement pharmacotherapy and address functional impairments that persist despite symptom control. Cognitive behavioral therapy for psychosis helps patients understand their experiences, develop coping strategies, and reduce distress associated with symptoms. Social skills training teaches interpersonal and independent living skills. Supported employment following the individual placement and support model achieves high rates of competitive employment. Family interventions including psychoeducation and communication skills training reduce relapse rates. Cognitive remediation targets cognitive deficits through structured exercises. Assertive community treatment provides intensive community-based support for patients with high service needs.

The recovery model provides a framework for understanding mental health beyond symptom reduction, emphasizing hope, personal empowerment, and meaningful life participation. Recovery does not necessarily mean cure or symptom elimination but rather living a satisfying and productive life despite ongoing illness. Person-centered care places the patient's goals and preferences at the center of treatment planning. Strengths-based approaches build on patient capabilities rather than focusing exclusively on deficits. Peer support from individuals with lived experience of mental illness provides unique benefits. The recovery model represents a fundamental shift from a purely medical approach to one that prioritizes the individual's own definition of wellbeing.

Long-term prognosis in schizophrenia varies considerably, contradicting earlier pessimistic views of inevitable decline. Approximately twenty percent of patients achieve good outcomes with minimal symptoms and good functioning, while another forty percent have moderate outcomes with some persistent symptoms but reasonable functioning. Approximately forty percent have more severe outcomes with persistent symptoms and significant functional impairment. Factors associated with better prognosis include later onset, female sex, good premorbid functioning, acute onset, presence of mood symptoms, short duration of untreated psychosis, and good initial treatment response. Comprehensive treatment addressing symptoms, cognition, and functioning optimizes outcomes.

<image>Panel A: A comparison of long-acting injectable antipsychotics showing formulations and dosing intervals. Panel B: A model of psychosocial interventions showing evidence-based treatments and their targets. Panel C: A diagram of recovery model principles showing hope, empowerment, and self-direction. Panel D: A prognostic factors chart showing predictors of better versus worse outcomes.</image>

Summary

• Psychosis involves hallucinations, delusions, and disorganized thinking or behavior; it occurs across many disorders and is not itself a diagnosis
• Schizophrenia requires at least two Criterion A symptoms for one month with at least six months total duration and functional decline
• Positive symptoms include hallucinations, delusions, and disorganization and respond to antipsychotic treatment
• Negative symptoms include alogia, avolition, anhedonia, asociality, and flat affect; they are harder to treat and predict functional outcomes
• Schizoaffective disorder requires psychosis plus mood episodes, with at least two weeks of psychosis occurring without mood symptoms
• First-line antipsychotic treatment typically involves second-generation agents; selection is individualized based on side effect profile and patient factors
• Metabolic monitoring of weight, glucose, and lipids is essential; highest risk with olanzapine and clozapine
• Extrapyramidal symptoms include acute dystonia, akathisia, parkinsonism, and tardive dyskinesia with distinct presentations and treatments
• Treatment-resistant schizophrenia requires failed trials of at least two antipsychotics; clozapine is the gold standard requiring ANC monitoring
• Recovery is possible with comprehensive treatment combining medication, psychosocial interventions, and support services

Key Terms

This content is subject to the MIT License. © 2024–2026 Hibbert School of Medicine.

Read this lecture as Markdown